BCL2 and prostate cancer: Dandekar et al. [22] reported that celecoxib-induced apoptosis in prostate cancer cells appeared to be accompanied by a reduction in the expression of anti-apoptotic proteins Bcl-2, Bcl-xL, and survivin.